Ocular Therapeutix Inc

OCUL remains in a Stage 2 advancing regime with its higher-low → higher-high uptrend intact, but the active Bullish Exhaustion pattern at the early July peak and a pullback into the 9/21 EMA zone amid neutral overbought/oversold conditions argue against immediate entry. Under a Speculative strategy, patience for a deeper, absorbed retracement into EMA and 50 DMA support is warranted before engagement.

• ↑SOLE1 trial achieved p=0.0006, surpassing approved anti-VEGF agents in wet AMD efficacy.
• ↑$667M cash balance as of March 31, 2026 funds operations through 2028.
• ↓Negative earnings yield and profitability scores indicate severe profit-generation challenges.